DEVELOPMENT AND IN-VITRO CHARACTERISATION OF ORAL SUSTAINED RELEASE MATRIX TABLETS OF GEMIGLIPTINAbstract
This project involves in the development of sustained release matrix tablets of Gemigliptin. Which is an oral anti-hyperglycemic agent designed for the management of non insulin dependent diabetes mellitus (NIDDM). The basic goal of therapy is to achieve a steady sate blood level that is therapeutically effective and non toxic for an extended period of time. The objective in dosage form design is to optimise the delivery of medication to achieve the control of therapeutic effect in the face of uncertain fluctuation in the in-vivo environment in which drug release takes place. Eight formulations of Gemigliptin 50mg were formulated by admixing with HPMC K4M, Carbopol were used as rate controlling polymers in different concentrations, Micro crystalline cellulose, Lactose, Talc, Magnesium stearate. Pre-formulation and post-formulation studies were carried out and the values obtained, satisfies the pharmacopoeial specifications. Several kinetic models were applied to the dissolution profiles to determine the drug release kinetics. Of all the formulations F5 exhibited gradual and completion extended release for Gemigliptin. The F5 (carbopol) with 1:1 ratio produced 89% drug release at end of the hour.
Srinivas Martha*, CH. Sagarika, K. Nandini, V. Seshavardhan and M. Kranthi kumar
Department of Pharmaceutics, Joginpally B.R. Pharmacy College, Yenkapally (V), Moinabad (M), Hyderabad- 500075, Telangana, India
27 April, 2016
18 July, 2016
13 August, 2016
01 September 2016